Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 19/20 | 1.00 |
| ▸ | MAPK9 | P45984 | 19/20 | 1.00 |
| ▸ | MAPK10 | P53779 | 5/20 | 1.00 |
| ▸ | CDK7 | P50613 | 1/20 | 0.70 |
| ▸ | CCNH | P51946 | 1/20 | 0.70 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.69 |
| ▸ | PIKFYVE | Q9Y2I7 | 2/20 | 0.65 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29403524 | 1.00 | MAPK8 (1.00) | MAPK8MAPK9MAPK10CDK7CCNH | |
| SCHEMBL23924257 | 1.00 | MAPK8 (1.00) | MAPK8MAPK9MAPK10CDK7CCNH | |
| SCHEMBL16171317 | 0.89 | MAPK8 (0.81) | MAPK8MAPK9MAPK10CDK7CCNH | |
| SCHEMBL23870567 | 0.87 | MAPK8 (0.78) | MAPK8MAPK9MAPK10CDK7CCNH | |
| SCHEMBL14979771 | 0.87 | MAPK8 (0.77) | MAPK8MAPK9MAPK10CDK7CCNH | |
| SCHEMBL18313157 | 0.83 | CDK7 (1.00) | MAPK8MAPK9MAPK10CDK7CCNH | |
| SCHEMBL22095472 | 0.83 | MAPK8 (0.87) | MAPK8MAPK9MAPK10CDK7CCNH | |
| SCHEMBL22095474 | 0.83 | MAPK8 (0.87) | MAPK8MAPK9MAPK10CDK7CCNH | |
| SCHEMBL29453371 | 0.83 | MAPK8 (0.87) | MAPK8MAPK9MAPK10CDK7CCNH | |
| SCHEMBL23924398 | 0.82 | MAPK8 (1.00) | MAPK8MAPK9MAPK10CDK7CCNH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220064249-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING INSULIN RESISTANCE, TYPE 2 DIABETES AND METABOLIC SYNDROME | LINK THERAPEUTICS, LLC | 2022-03-03 | — | — | US | claimed |
| US-20210324031-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING LEPTIN RESISTANCE, OBESITY, DIABETES MELLITUS AND METABOLIC SYNDROME | LINK THERAPEUTICS, LLC | 2021-10-21 | — | — | US | claimed |
| US-20260024617-A1 | METHODS AND SYSTEMS FOR PERSONALIZED THERAPIES | SCIPHER MEDICINE CORP (US) | 2026-01-22 | — | — | US | disclosed |
| US-12435116-B2 | Compounds, compositions, methods, and uses for treating insulin resistance, type 2 diabetes and metabolic syndrome | LINK THERAPEUTICS, LLC | 2025-10-07 | — | — | US | disclosed |
| US-12351822-B2 | Stem cell culture systems for columnar epithelial stem cells, and uses related thereto | UNIVERSITY OF HOUSTON SYSTEM (US) | 2025-07-08 | — | — | US | disclosed |
| US-20240203555-A1 | METHODS AND SYSTEMS FOR THERAPY MONITORING AND TRIAL DESIGN | SCIPHER MEDICINE CORP (US) | 2024-06-20 | — | — | US | disclosed |
| US-20240153580-A1 | METHODS AND SYSTEMS FOR PERSONALIZED THERAPIES | Scipher Medicine Corporation | 2024-05-09 | — | — | US | disclosed |
| US-20230357714-A1 | STEM CELL CULTURE SYSTEMS FOR COLUMNAR EPITHELIAL STEM CELLS, AND USES RELATED THERETO | UNIVERSITY OF HOUSTON SYSTEM (US) | 2023-11-09 | — | — | US | disclosed |
| US-11725185-B2 | Stem cell culture systems for columnar epithelial stem cells, and uses related thereto | UNIVERSITY OF HOUSTON SYSTEM (US) | 2023-08-15 | — | — | US | disclosed |
| US-20220153730-A9 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-19 | — | — | US | disclosed |
| US-20220153730-A9 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-19 | — | — | US | disclosed |
| US-10981903-B2 | Inhibitors of c-Jun-N-terminal kinase (JNK) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20200087295-A9 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-03-19 | — | — | US | disclosed |
| EP-3569598-A1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | Dana Farber Cancer Institute, Inc. (US) | 2019-11-20 | — | — | EP | disclosed |
| US-20190248778-A1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-08-15 | — | — | US | disclosed |
| US-20160368910-A1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-12-22 | — | — | US | disclosed |
| US-20160368910-A1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-12-22 | — | — | US | disclosed |
| US-9382239-B2 | Inhibitors of c-Jun-N-terminal kinase (JNK) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-20140309249-A1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | Dana-Farber Cancer Intitute, Inc. (US) | 2014-10-16 | — | — | US | disclosed |
| WO-2013074986-A1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435116-B2 | Compounds, compositions, methods, and uses for treating insulin resistance, type 2 diabetes and metabolic syndrome | INSR, IRS1, INSRR | MAPK8 1803/4885MAPK9 2549/4885MAPK10 2203/4885 |
| US-10981903-B2 | Inhibitors of c-Jun-N-terminal kinase (JNK) | CNKSR1, MAPK1, MAP3K1 | MAPK8 52/4885MAPK9 34/4885MAPK10 44/4885 |
| US-20200087295-A9 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | CNKSR1, MAPK1, MAP3K1 | MAPK8 52/4885MAPK9 34/4885MAPK10 44/4885 |
| US-20210324031-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING LEPTIN RESISTANCE, OBESITY, DIABETES MELLITUS AND METABOLIC SYNDROME | LIPE, GPR119, FABP4 | MAPK8 1958/4885MAPK9 2843/4885MAPK10 2119/4885 |
| US-20220153730-A9 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | CNKSR1, MAPK1, MAP3K1 | MAPK8 52/4885MAPK9 34/4885MAPK10 44/4885 |
| US-20260024617-A1 | METHODS AND SYSTEMS FOR PERSONALIZED THERAPIES | SET, SSB, CNKSR1 | MAPK8 3804/4885MAPK9 3215/4885MAPK10 4181/4885 |
| US-20160368910-A1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | CNKSR1, MAPK1, MAP3K1 | MAPK8 52/4885MAPK9 34/4885MAPK10 44/4885 |
| US-20140309249-A1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | CNKSR1, MAPK1, MAP3K1 | MAPK8 52/4885MAPK9 34/4885MAPK10 44/4885 |
| US-20190248778-A1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | CNKSR1, MAPK1, MAP3K1 | MAPK8 52/4885MAPK9 34/4885MAPK10 44/4885 |
| US-20220064249-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING INSULIN RESISTANCE, TYPE 2 DIABETES AND METABOLIC SYNDROME | INSR, IRS1, INSRR | MAPK8 1803/4885MAPK9 2549/4885MAPK10 2203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.